Рынок гормона роста достигнет 19,3 млрд долларов к 2033 году благодаря новым терапиям

09-09-2026 09:16 AM CET | Health & Medicine Press release from: DataM intelligence 4 Market Research LLP According to DataM Intelligence, the growth hormone deficiency market size reached USD 7.74 billion in 2025 and is projected to reach USD 19.3 billion by 2033, growing at a CAGR of 12.1% during the forecast. The increasing diagnosis of pediatric and adult growth hormone deficiency, together with improved treatment options and greater awareness among healthcare professionals, continues to support market growth. The growth hormone deficiency market trends indicate increasing acceptance of long-acting recombinant growth hormone therapies that reduce injection frequency and improve patient adherence. Pharmaceutical companies are also introducing patient-friendly delivery devices and expanding treatment indications. Download a free sample of the market: https://www.datamintelligence.com/download-sample/growth-hormone-deficiency-market?akash Recent Developments in the Growth Hormone Deficiency Market January 2026: Novo Nordisk announced broader commercial availability of its once-weekly growth hormone therapy across additional international markets, helping improve treatment adherence for pediatric and adult patients. February 2026: Pfizer Inc. expanded research activities focused on long-acting recombinant human growth hormone formulations designed to reduce treatment burden while maintaining clinical effectiveness. March 2026: Ascendis Pharma presented additional long-term clinical findings supporting the effectiveness and safety profile of its once-weekly growth hormone therapy for children with growth hormone deficiency. April 2026: Merck KGaA strengthened collaborations with endocrinology research centers to evaluate individualized treatment approaches for growth hormone deficiency management across multiple patient populations. United States Recent Developments February 2026: Ascendis Pharma continued expanding patient support programs across the United States to improve access to once-weekly growth hormone therapy for eligible pediatric patients. March 2026: Pfizer enhanced educational initiatives for endocrinologists in the United States to support earlier diagnosis and appropriate treatment selection for growth hormone deficiency. Japan Recent Developments February 2026: Novo Nordisk expanded physician education programs in Japan to increase awareness of long-acting growth hormone treatment options and patient monitoring practices. April 2026: Japanese healthcare providers continued adopting long-acting recombinant growth hormone therapies as part of routine endocrine care, supporting improved treatment adherence among eligible patients. Mergers and Acquisitions in the Growth Hormone Deficiency Market January 2026: A global biopharmaceutical company completed the acquisition of a biotechnology firm specializing in peptide-based endocrine therapies, strengthening its hormone treatment portfolio. March 2026: An international pharmaceutical manufacturer acquired rights to commercialize recombinant growth hormone products in selected Asia-Pacific markets, expanding its regional presence. May 2026: A specialty pharmaceutical company entered an acquisition agreement with a rare disease drug developer to broaden its endocrinology pipeline and improve access to hormone replacement therapies. June 2026: A biotechnology company acquired advanced drug delivery technology designed to improve long-acting hormone therapies and support future product development. Customize Report Get detailed insights tailored to your specific requirements: https://www.datamintelligence.com/buy-now-page?report=growth-hormone-deficiency-market?akash Strategic Opportunities in the Growth Hormone Deficiency Market Expansion of Long-Acting Therapies Long-acting growth hormone treatments continue to create new opportunities across the growth hormone deficiency market. Reduced injection frequency can improve patient convenience, encourage better treatment adherence, and support long-term disease management. Companies investing in these therapies are well positioned to strengthen their presence in the market. Earlier Diagnosis Through Greater Awareness Improving awareness among healthcare professionals and parents can support earlier diagnosis of growth hormone deficiency. Better screening practices and timely referrals to endocrinology specialists can help patients begin treatment sooner, creating additional opportunities for healthcare providers and pharmaceutical manufacturers. Growth Hormone Deficiency Market Segmentation By Type • Pediatric (approximately 75%) - Children account for the majority of diagnosed and treated growth hormone deficiency cases • Adult By Treatment • Pharmacological Therapy (approximately 95%) - Recombinant human growth hormone remains the standard of care for managing growth hormone deficiency • Human Pituitary Gland Extracts • Others By Route of Administration • Subcutaneous Injection (approximately 98%) - Most approved growth hormone products are administered through subcutaneous injection • Intravenous • Intramuscular • Others By Distribution Channel • Hospital Pharmacy • Retail Pharmacy • Online Pharmacy Key Players in the Growth Hormone Deficiency Market • Pfizer Inc. • Novo Nordisk A/S • Eli Lilly and Company • Sandoz AG • Merck KGaA Novo Nordisk is a global leader in endocrine therapies with a strong portfolio of growth hormone products. The company continues expanding access to once-weekly treatment options while supporting physician education and patient adherence programs. Pfizer Inc. Pfizer develops recombinant growth hormone therapies for pediatric growth hormone deficiency and continues to invest in long-acting treatment approaches designed to reduce injection frequency and improve patient convenience. Purchase Report Get the complete report with detailed market insights and analysis: https://www.datamintelligence.com/customize/growth-hormone-deficiency-market?akash Regional Analysis The United States remains the largest contributor within North America. Early diagnosis, favorable reimbursement for eligible patients, specialized pediatric endocrinology centers, and continued product launches support sustained demand for growth hormone deficiency treatments. Europe maintains a stable market supported by established healthcare systems and clinical guidelines for diagnosing and managing growth hormone deficiency. Increasing adoption of long-acting formulations is strengthening treatment adherence across several countries. Japan remains an important market because of its advanced endocrinology care, strong regulatory standards, and continued use of recombinant growth hormone therapies for eligible pediatric and adult patients. Ongoing physician education and patient monitoring programs continue supporting treatment adoption. Conclusion The growth hormone deficiency market continues to expand as awareness, early diagnosis, and improved treatment options become more widely available. Long-acting growth hormone therapies are helping reduce treatment burden while supporting better adherence for both pediatric and adult patients. The continued focus on recombinant hormone therapy, broader treatment access, and ongoing clinical research is expected to support the growth hormone deficiency market forecast. As healthcare providers place greater emphasis on individualized patient care, the industry is expected to maintain steady long-term development. For more insights on the market, please visit the DataM Intelligence page: https://www.datamintelligence.com/research-report/growth-hormone-deficiency-market Frequently Asked Questions 1. What is driving the growth hormone deficiency market growth? Increasing diagnosis rates, wider availability of recombinant growth hormone therapies, and growing adoption of long-acting treatments are supporting market growth. 2. Which treatment segment leads the growth hormone deficiency market? Pharmacological therapy remains the leading segment because recombinant growth hormone continues to be the standard treatment for growth hormone deficiency. 3. Which region holds a leading position in the growth hormone deficiency market? North America leads the market due to advanced healthcare infrastructure, early diagnosis, strong reimbursement support, and the presence of leading pharmaceutical companies. Explore More Japan Market Research Reports for In-Depth Industry Analysis: https://www.datamintelligence.com/jp-market-research-report Contact Us: Sai Kiran Business Development Manager DataM Intelligence 4market Research LLP 6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039 USA: +1 877-441-4866 Email: [email protected] About Us: DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology. Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele. This release was published on openPR. Permanent link to this press release: Copy Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release. You can edit or delete your press release Growth Hormone Deficiency Market Size to Reach USD 19.3 Billion by 2033 as Long-Acting Therapies and Improved Patient Care Expand Treatment Adoption here News-ID: 4625786 • Views: … Japan Cogeneration Equipment Market Size to Reach USD 56.02 Billion by 2033 as E … According to DataM Intelligence, the global cogeneration equipment market size reached USD 32.07 Billion in 2025 and is projected to reach USD 56.02 billion by 2033, registering a CAGR of 7.22% during the forecast. The increasing use of combined heat and power systems across manufacturing, healthcare, utilities, and commercial facilities continues to support market growth. Download a free sample of the market: https://www.datamintelligence.com/download-sample/cogeneration-equipment-market?akash USA: Recent Developments January 2026 (US): … 09-08-2026 | Health & Medicine DataM intelligence 4 Market Research LLP MRI Systems Market to Reach US$11.72 Billion by 2033 as U.S. Hospitals Reprice S … CHICAGO - September 2026: U.S. MRI purchasing is entering a different capital-allocation cycle. Hospitals are no longer comparing systems principally on field strength and image quality. Magnet architecture, room preparation, helium dependence, scan automation, technologist workload, examination duration and system uptime increasingly determine whether a new installation can generate an acceptable return. According to DataM Intelligence, the global MRI Systems Market reached US$6.62 billion in 2024 and is projected to … Temperature Controlled Packaging Market to Reach USD 54.1 Billion by 2033 as U.S … Texas, USA - September 2026: U.S. temperature-controlled packaging is becoming a route-to-market decision rather than a simple insulated-box purchase. Food and beverage companies, meal-delivery networks, specialty distributors, and healthcare shippers increasingly need packaging that can protect products across unpredictable dwell times, last-mile delivery, and seasonal temperature extremes without relying on refrigerated infrastructure at every handoff. According to DataM Intelligence, the global Temperature Controlled Packaging Market reached USD 28.2 billion in … 09-08-2026 | Health & Medicine DataM intelligence 4 Market Research LLP Electronic Health Records Market to Reach US$50.78 Billion by 2033 as U.S. Hospi … Texas, USA - September 2026: The U.S. electronic health record market is moving beyond basic digitization. Hospitals already operate extensive EHR infrastructure; the next budget cycle is being determined by whether platforms can reduce documentation time, connect specialty systems, satisfy federal interoperability requirements, and translate clinical activity into accurate reimbursement. According to DataM Intelligence, the global Electronic Health Records Market reached US$32.97 billion in 2024 and is projected to reach … All 5 Releases 07-02-2025 | Health & Medicine The Business Research Company Surge In Hormone Imbalance Disorders Fuels Growth Of Hormone Therapy Market Emer … Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations. What Is the Expected CAGR for the Hormone Therapy Market Through 2025? The size of the hormone therapy market has experienced significant growth in the past few years. It is expected to increase from $19.7 billion in 2024 to $21.1 billion in 2025, at a compound annual growth rate (CAGR) of 7.1%. The growth … 06-04-2025 | Health & Medicine DataM Intelligence 4 Market Research LLP Parathyroid Hormone Market Overview: How Parathyroid Hormone Affects Health & Cl … Parathyroid Hormone Market is predicted to grow at a CAGR 3.4% during the forecast period (2024-2031). Parathyroid Hormone Market Report by DataM Intelligence delivers deep insights and analysis into the latest market trends, growth opportunities, and emerging challenges. Designed to help businesses make smarter, faster decisions, our reports combine both data-driven analysis and expert perspectives. At DataM Intelligence, we're committed to turning complex market landscapes into clear, actionable strategies so … 03-14-2025 | Health & Medicine Evolve Business Intelligence Estrogen Hormone Replacement: A Vital Segment Driving Growth in the Hormone Repl … The Hormone Replacement Therapy (HRT) market is experiencing renewed interest, driven by an aging population and a growing understanding of hormonal health. Within this market, the estrogen hormone replacement segment stands out as a high-opportunity area, offering relief from menopausal symptoms and addressing various health concerns. Market Dynamics and Growth Drivers Estrogen HRT plays a crucial role in managing menopausal symptoms, such as hot flashes, night sweats, and vaginal dryness. Beyond symptom … 06-13-2023 | Business, Economy, Finances, B … Growth Plus Reports Klinefelter Syndrome Hormone Therapy Market - Balancing Hormones, Unleashing Pot … Newark, New Castle, USA: The "Klinefelter Syndrome Hormone Therapy Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Klinefelter Syndrome Hormone Therapy Market: https://www.growthplusreports.com/report/klinefelter-syndrome-hormone-therapy-market/8775 This latest report researches the … 06-01-2023 | Business, Economy, Finances, B … Growth Plus Reports Human Growth Hormone Market - Elevating Lives, Amplifying Growth: Innovations in … Newark, New Castle, USA - new report, titled Human Growth Hormone Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Human Growth Hormone market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Human Growth Hormone market. The report offers an overview of … 02-25-2022 | Advertising, Media Consulting, … ReportsnReports Hormone Replacement Therapy Market Report- Segment by Application Menopause, Hyp … The Hormone Replacement Therapy Market research report presents an intensive and coordinated exploration of the current circumstance, market key elements, Hormone Replacement Therapy Market methodologies, and central participants' development in the business. The investigation helps controllers and corporate leaders in developing cost-effective decisions. Hormone Replacement Therapy Market provides an evenhanded and extensive assessment of existing examples, factors, obstacles, limits, headway, possibilities/quick development areas that will help partners create business plans …